2026 DIA China Annual Meeting concluded successfully on May 16 at  Zhangjiang Science Hall in Shanghai. The conference brought together experts, academics and industry leaders from the global healthcare and pharmaceutical sectors to feature in-depth discussions on innovative drug development, regulatory science, and clinical practice. As a professional service provider specializing in clinical endpoint assessment,Pixel Wiser staged an impressive presence at Booth ,bring along its professional team and three core service offerings. We engaged in fruitful exchanges with guests from pharmaceutical companies, CROs and research institutions, jointly exploring new pathways for the high-quality development of clinical trials.

During the conference, Pixel Wiser showcased its three core services—BIRC, RTQA and Cardiac Safety Assessment—which fully cater to sponsors’ key demands across the entire clinical trial life cycle. These services fully demonstrate our professional expertise in clinical endpoint assessment, helping companies efficiently execute their R&D strategies and accelerate the market launch of innovative medicines.

The booth remained bustling with visitors throughout the conference. Our professional team provided one-on-one consulting services for all partners, engaging in in-depth discussions on service processes, technical standards, compliance requirements and project cases, thereby precisely meeting the diverse needs of different enterprises.

While the 2026 DIA Annual Meeting has come to a close, Pixel Wiser will continue to deepen our expertise in clinical endpoint assessment and work hand in hand with partners to drive high-quality and internationally standardized development of the new drug R&D industry.